CoChat
Sign Up
Cited by 12

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Brain Expression, Physiological Regulation and Role in Motivation and Associative Learning of Peroxisome Proliferator-activated Receptor γ

Moosecker, Susanne, Pissioti, Anna, Leidmaa, Este, Harb, Mazen R., Dioli, Chrysoula, Gassen, Nils C., Yu, Shuang, Gazea, Mary, Catania, Caterina, Anderzhanova, Elmira, Patchev, Alexandre V., Kühne, Claudia, Stoffel, Rainer, Sotiropoulos, Ioannis, Almeida, Osborne F.X.·2021·Neuroscience
DOI 10.1016/j.neuroscience.2021.10.029
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuroscience.2021.10.029

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 72

  1. Ahmadian, 2013, PPARγ signaling and metabolism: the good, the bad and the future, Nat Med, 19, 557, 10.1038/nm.3159 · DOI · Paper page
  2. Alford, 2017, Obesity as a risk factor for Alzheimer's disease: weighing the evidence, Obes Rev, 19, 269, 10.1111/obr.12629 · DOI
  3. Arnold, 2018, Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums, Nat Rev Neurol, 14, 168, 10.1038/nrneurol.2017.185 · DOI · Paper page
  4. Barrera, 2018, Probing the role of PPARγ in the regulation of late-onset Alzheimer's disease-associated genes, PLoS One, 13, e0196943, 10.1371/journal.pone.0196943 · DOI · Paper page
  5. Braissant, 1998, Differential expression of peroxisome proliferator-activated eceptor-alpha, -beta, and -gamma during rat embryonic development, Endocrinology, 139, 2748, 10.1210/endo.139.6.6049 · DOI
  6. Breidert, 2002, Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease, J Neurochem, 82, 615, 10.1046/j.1471-4159.2002.00990.x · DOI
  7. Cho, 2013, Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons, J Neurochem, 126, 685, 10.1111/jnc.12264 · DOI
  8. Denner, 2012, Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways, J Neurosci, 32, 16725, 10.1523/JNEUROSCI.2153-12.2012 · DOI
  9. Diano, 2011, Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity, Nat Med, 17, 1121, 10.1038/nm.2421 · DOI
  10. Domi, 2019, Activation of PPARγ attenuates the expression of physical and affective nicotine withdrawal symptoms through mechanisms involving amygdala and hippocampus neurotransmission, J Neurosci, 39, 9864, 10.1523/JNEUROSCI.1922-19.2019 · DOI
  11. Domi, 2016, Genetic deletion of neuronal PPARγ enhances the emotional response to acute stress and exacerbates anxiety: An effect reversed by rescue of amygdala PPARγ function, J Neurosci, 36, 12611, 10.1523/JNEUROSCI.4127-15.2016 · DOI · Paper page
  12. Escribano, 2010, Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology, Neuropsychopharmacology, 35, 1593, 10.1038/npp.2010.32 · DOI · Paper page
  13. Ferretti, 2018, Sex differences in Alzheimer disease - the gateway to precision medicine, Nature Rev Neurol, 14, 457, 10.1038/s41582-018-0032-9 · DOI · Paper page
  14. Fotio, 2021, Activation of peroxisome proliferator-activated receptor γ reduces alcohol drinking and seeking by modulating multiple mesocorticolimbic regions in rats, Neuropsychopharmacology, 46, 360, 10.1038/s41386-020-0754-4 · DOI
  15. Govindarajulu, 2018, Signaling mechanisms of selective PPARγ modulators in Alzheimer's disease, PPAR Res, 2018, 1, 10.1155/2018/2010675 · DOI
  16. Gofflot, 2007, Systematic gene expression mapping clusters nuclear receptors according to their function in the brain, Cell, 131, 405, 10.1016/j.cell.2007.09.012 · DOI
  17. Harb, 2014, Altered motivation masks appetitive learning potential of obese mice, Front Behav Neurosci, 8, 377, 10.3389/fnbeh.2014.00377 · DOI
  18. Heneka, 2015, Neuroinflammation in Alzheimer's disease, Lancet Neurol, 14, 388, 10.1016/S1474-4422(15)70016-5 · DOI · Paper page
  19. Heneka, 2005, Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice, Brain, 128, 1442, 10.1093/brain/awh452 · DOI · Paper page
  20. Home, 2009, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, Lancet, 373, 2125, 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
  21. Horner, 2013, The touchscreen operant platform for testing learning and memory in rats and mice, Nat Protoc, 8, 1961, 10.1038/nprot.2013.122 · DOI
  22. Hussain, 2020, Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence, Neurol Sci, 41, 3697, 10.1007/s10072-020-04494-3 · DOI
  23. Isaac, 2006, Manganese treatment modulates the expression of peroxisome proliferator-activated receptors in astrocytoma and neuroblastoma cells, Neurochem Res, 31, 1305, 10.1007/s11064-006-9173-0 · DOI
  24. Issemann, 1990, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, Nature, 347, 645, 10.1038/347645a0 · DOI · Paper page
  25. Jahrling, 2014, PPARγ recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement, J Neurosci, 34, 4054, 10.1523/JNEUROSCI.4024-13.2014 · DOI
  26. Inestrosa, 2005, Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling, Exp Cell Res, 304, 91, 10.1016/j.yexcr.2004.09.032 · DOI
  27. Jojo, 2019, Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease, J Clin Pharm Ther, 44, 337, 10.1111/jcpt.12808 · DOI
  28. Kitamura, 1999, Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains, Biochem Biophys Res Commun, 254, 582, 10.1006/bbrc.1998.9981 · DOI
  29. Krishna S, Cheng B, Sharma DR, Cheng B, Sharma DR, Yadav S, Stempinski ES, Mamtani S, et al (2021). PPAR-γ activation enhances myelination and neurological recovery in premature rabbits with intraventricular hemorrhage. Proc Natl Acad Sci USA 118, e2103084118. DOI: 10.1073/pnas.2103084118. · DOI
  30. Kuwahara, 1999, Prions prevent neuronal cell-line death, Nature, 400, 225, 10.1038/22241 · DOI
  31. Lee, 2014, Change of peroxisome proliferator-activated receptor γ expression pattern in the gerbil dentate gyrus after transient global cerebral ischemia, Anat Cell Biol, 47, 111, 10.5115/acb.2014.47.2.111 · DOI
  32. Levin, 2016, Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors, Nat Rev Mol Cell Biol, 17, 783, 10.1038/nrm.2016.122 · DOI
  33. Lewandowski, 2020, Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How, Neurobiol Dis, 139, 104811, 10.1016/j.nbd.2020.104811 · DOI · Paper page
  34. Lewis, 2011, Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study, Diabetes Care, 34, 916, 10.2337/dc10-1068 · DOI · Paper page
  35. Liu, 2015, PPARγ mRNA in the adult mouse hypothalamus: distribution and regulation in response to dietary challenges, Front Neuroanat, 9, 120, 10.3389/fnana.2015.00120 · DOI
  36. Lu, 2011, Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones, Nat Med, 17, 618, 10.1038/nm.2332 · DOI
  37. Lyra, 2019, Insulin resistance as a shared pathogenic mechanism between depression and Type 2 diabetes, Front Psychiatry, 10, 57, 10.3389/fpsyt.2019.00057 · DOI
  38. Moreno, 2004, Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS, Neuroscience, 123, 131, 10.1016/j.neuroscience.2003.08.064 · DOI
  39. Moosecker, 2019, Activated PPARγ abrogates misprocessing of amyloid precursor protein, Tau missorting and synaptotoxicity, Front Cell Neurosci, 13, 239, 10.3389/fncel.2019.00239 · DOI
  40. Neitzel, 2021, KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease, Nat Commun, 12, 10.1038/s41467-021-23755-z · DOI · Paper page
  41. Nenov, 2015, Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPARγ agonism, J Neurophysiol, 113, 1712, 10.1152/jn.00419.2014 · DOI
  42. Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 · DOI · Paper page
  43. Norton, 2014, Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data, Lancet Neurol, 13, 788, 10.1016/S1474-4422(14)70136-X · DOI · Paper page
  44. Patrone, 2014, Diabetes drugs and neurological disorders: new views and therapeutic possibilities, Lancet Diabetes Endocrinol, 2, 256, 10.1016/S2213-8587(13)70125-6 · DOI
  45. Paxinos G, Halliday G, Watson C, Koutcherov Y, Wang HQ Atlas of the Developing Mouse Brain at E17.5, P0, and P6. London; Amsterdam: Elsevier Academic Press, 2007. (ISBN 9780125476225)
  46. Pedersen, 2006, Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice, Exp Neurol, 199, 265, 10.1016/j.expneurol.2006.01.018 · DOI
  47. Pfaffl, 2001, A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acids Res, 29, 10.1093/nar/29.9.e45 · DOI · Paper page
  48. Podcasy, 2016, Considering sex and gender in Alzheimer disease and other dementias, Dialogues Clin Neurosci, 18, 437, 10.31887/DCNS.2016.18.4/cepperson · DOI
  49. P, 2021, Glitazones activate PGC-1α signaling via PPAR-γ: A promising strategy for antiparkinsonism therapeutics, ACS Chem Neurosci, 12, 2261, 10.1021/acschemneuro.1c00085 · DOI
  50. Puigserver, 2003, Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator, Endocr Rev, 24, 78, 10.1210/er.2002-0012 · DOI · Paper page
  51. Ransohoff, 2016, How neuroinflammation contributes to neurodegeneration, Science, 353, 777, 10.1126/science.aag2590 · DOI · Paper page
  52. Risner, 2006, Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease, Pharmacogenomics J, 6, 246, 10.1038/sj.tpj.6500369 · DOI · Paper page
  53. Rodríguez-Pascau, 2021, The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy, Sci Transl Med, 13, 10.1126/scitranslmed.abc0555 · DOI · Paper page
  54. Rodriguez-Rivera, 2011, Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status, Behav Brain Res, 216, 255, 10.1016/j.bbr.2010.08.002 · DOI
  55. Ryan, 2011, A role for central nervous system PPAR-γ in the regulation of energy balance, Nat Med, 17, 623, 10.1038/nm.2349 · DOI
  56. Sarruf, 2009, Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis, Endocrinology, 150, 707, 10.1210/en.2008-0899 · DOI
  57. Sato, 2011, Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease, Neurobiol Aging, 32, 1626, 10.1016/j.neurobiolaging.2009.10.009 · DOI · Paper page
  58. Schwandt, 2020, PPARγ activation by pioglitazone does not suppress cravings for alcohol, and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: a randomized controlled proof of principle study, Psychopharmacology (Berl), 237, 2367, 10.1007/s00213-020-05540-w · DOI
  59. Šimić, 2021, Understanding emotions: origins and roles of the amygdala, Biomolecules, 11, 823, 10.3390/biom11060823 · DOI
  60. Skerrett, 2015, Combined liver X receptor/peroxisome proliferator-activated receptor γ agonist treatment reduces amyloid β levels and improves behavior in amyloid precursor protein/presenilin 1 mice, J Biol Chem, 290, 21591, 10.1074/jbc.M115.652008 · DOI
  61. Simeone, 2017, Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy, Exp Neurol, 287, 54, 10.1016/j.expneurol.2016.08.006 · DOI
  62. Soccio, 2014, Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes, Cell Metab, 20, 573, 10.1016/j.cmet.2014.08.005 · DOI · Paper page
  63. Sotiropoulos, 2011, Stress acts cumulatively to precipitate Alzheimer’s disease-like Tau pathology and cognitive deficits, J Neurosci, 31, 7840, 10.1523/JNEUROSCI.0730-11.2011 · DOI
  64. Tontonoz, 1994, mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer, Genes Dev, 8, 1224, 10.1101/gad.8.10.1224 · DOI
  65. Tufano, 2020, Is there a future for PPARs in the treatment of neuropsychiatric disorders?, Molecules, 25, 1062, 10.3390/molecules25051062 · DOI
  66. Vanaveski, 2021, PGC-1α signaling increases GABA(A) receptor subunit α2 expression, GABAergic neurotransmission and anxiety-like behavior in mice, Front Mol Neurosci, 14, 10.3389/fnmol.2021.588230 · DOI
  67. Villapol, 2018, Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation, Cell Mol Neurobiol., 38, 121, 10.1007/s10571-017-0554-5 · DOI
  68. Warden, 2016, Localization of PPAR isotypes in the adult mouse and human brain, Sci Rep, 6, 27618, 10.1038/srep27618 · DOI
  69. Willson, 2000, The PPARs: from orphan receptors to drug discovery, J Med Chem, 43, 527, 10.1021/jm990554g · DOI · Paper page
  70. Xu, 2014, Rosiglitazone prevents amyloid-β oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number, J Alzheimers Dis, 39, 239, 10.3233/JAD-130680 · DOI
  71. Yang, 2013, Non-receptor-tyrosine kinases integrate fast glucocorticoid signaling in hippocampal neurons, J Biol Chem., 288, 23725, 10.1074/jbc.M113.470146 · DOI
  72. Zolezzi, 2017, PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation, Biol Rev Camb Philos Soc, 92, 2046, 10.1111/brv.12320 · DOI

Cited by

Sorted by citations

Metadata

Authors
Moosecker, S., Pissioti, A., Leidmaa, E., Harb, M. R., Dioli, C., Gassen, N. C., Yu, S., Gazea, M., Catania, C., Anderzhanova, E., Patchev, A. V., Kühne, C., Stoffel, R., Sotiropoulos, I., & Almeida, O. F. X.
Venue
Neuroscience
Publisher
Elsevier BV
Published
2021-12
Volume
479
Pages
91-106
ISSN
0306-4522
DOI
10.1016/j.neuroscience.2021.10.029
Cited by
12
References
12
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review